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1607-551X/Copyright ª 2016, Kaohsiu
BY-NC-ND license (http://creativecomAbstract During surgery, changes in intraocular pressure (IOP) can be observed resulting
from several factors, such as airway manipulations and drugs used. We aimed to investigate
the effects of sugammadex and neostigmine on IOP, hemodynamic parameters, and complica-
tions after extubation. Our study comprised 60 patients, aged 18e65 years, with a risk status of
the American Society of Anesthesiologists IeII who underwent arthroscopic surgery under gen-
eral anesthesia. The patients were randomly assigned into two groups. At the end of the sur-
gery, the neuromuscular block was reversed using neostigmine (50 mg/kg) plus atropine (15 mg/
kg) in Group 1, and sugammadex (4 mg/kg) in Group 2. Neuromuscular blockade was monitored
using acceleromyography and a train-of-four mode of stimulation. IOP was measured before
induction and at 30 seconds, 2 minutes, and 10 minutes after extubation. A Tono-Pen XL appla-
nation tonometer was used to measure IOP. This showed that elevation in IOP of patients
reversed using sugammadex was similar to that recorded in patients reversed using neostig-
mineeatropine. When heart rate was compared, there was a significant difference between
basal values and those obtained at 30 seconds and 10 minutes after extubation in the neostig-
mineeatropine group. Extubation time (time from withdrawal of anesthetic gas to extubation)
was significantly shorter in the sugammadex group (p Z 0.003) than in the neostigmineeclare no conflicts of interest.
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Effect of reversal agents on intraocular pressure 81eatropine group. The postextubation IOP values of the sugammadex group were similar to the
neostigmineeatropine group. Extubation time (time from withdrawal of anesthetic gas to ex-
tubation) was significantly shorter in the sugammadex group (p Z 0.003) than in the neostig-
mineeatropine group.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Several factors are involved in the pathogenesis of glau-
coma, which is one of the leading causes of blindness
worldwide. Among them, elevation in intraocular pressure
(IOP) is the most definitive and confirmed cause [1]. IOP is
influenced by many factors including genetics, age,
refractive errors, and race [2]. Both surgical procedures
and anesthesia can cause changes in IOP during surgery
from such things as the patient’s position, tourniquet use,
airway manipulations (tracheal intubation, laryngeal mask
insertion, etc.), and drugs used in anesthesia [3e5].
During general anesthesia, airway interventions can
cause undesired elevations in IOP by increasing blood
pressure and ocular blood flow [6]. Although it is known
that tracheal intubation causes elevation in IOP, intubation
is still used because it provides better airway management
[7]. In addition, during tracheal intubation, IOP can in-
crease because of factors such as the patient coughing or
holding his or her breath [8]. Alteration in IOP during sur-
gery is of particular importance in pediatric glaucoma cases
or in cases involving penetrating intraocular injuries. In
pediatric cases, there is a need for examination under
anesthesia to perform IOP measurements; however, anes-
thetic agents can cause changes in IOP, making it difficult to
obtain reliable results [9].
Acute elevation in IOP is a serious condition in cases with
ocular perforation, and the stress response during tracheal
intubation and extubation can cause such elevation, which
is attributed to the sympathetic nervous system [7,10,11].
It has been suggested that adrenergic activation leads to
increased central venous pressure and subsequent IOP
elevation from the increased episcleral venous flow [12].
Both tracheal intubation and extubation cause activa-
tion of the sympathetic nervous system, which might lead
to undesired effects, such as increased heart rate and
arterial blood pressure in patients with hypertension,
ischemic heart disease, and cerebrovascular disorders [13].
Sugammadex is now being used as an alternative to
decurarization with acetylcholinesterase inhibitors. It is a
selective relaxant that reverses the effects of the neuro-
muscular blockers rocuronium or vecuronium [14,15].
Postoperative residual block is associated with mortal-
ity, and it has been demonstrated that sugammadex de-
creases the incidence of residual block [16]. Sugammadex is
a preferred agent in clinical practice because it provides for
rapid recovery with no undesired adverse events. In this
prospective randomized study, we aimed to investigate the
effects of sugammadex and neostigmine on IOP, hemody-
namic parameters, and complications after extubation.Methods
The study was approved by the Institutional Ethics Com-
mittee of Mustafa Kemal University, Faculty of Medicine,
Hatay, Turkey (Ethic Committee Approval Date: 04.10.2012;
Approval Number: 08; Chairman: Selim Turhanoglu). The
study has been registered in the Australian New Zealand
Clinical Trials Registry at http://www.anzctr.org.au,
registration number: ACTRN12614000651684.
All patients gave written informed consent before
participating. The study comprised 60 patients aged
18e65 years with American Society of Anesthesiologists IeII
risk status who underwent arthroscopic surgery under
general anesthesia. The patients were randomly assigned
into two groups (neostigmin group, Group 1; and sugam-
madex group, Group 2) by computer-generated random
numbers. Patients with hypertension or other chronic dis-
eases, those who had previously undergone ocular surgery,
and those with previous ocular diseases were excluded. In
addition, patients allergic to tetracaine or other agents
used in anesthesia were excluded.
Standard monitoring comprising electrocardiogram,
noninvasive blood pressure measurements (systolic and
diastolic blood pressures), heart rate, and peripheral
arterial oxygen saturation was performed during surgery. In
addition to standard monitoring, train-of-four (TOF-Watch
SX; Organon Ireland Ltd., Dublin, Ireland) was used to
monitor the level of neuromuscular blockade. After
inserting an intravenous line, anesthesia was induced using
propofol (2.5 mg/kg) and fentanyl (1.0 mg/kg), and after
loss of eyelash reflex and calibration and stabilization of
the TOF-Watch SX, rocuronium bromide (0.6 mg/kg) was
administered in both groups. After administration of the
appropriate bolus dose of rocuronium bromide, the patient
was intubated as soon as the first response to the TOF
stimulus (T1) decreased to below 10%. Anesthesia was
maintained using desflurane 4e6% (3 L/min) in a 50:50%
oxygen/air mixture. Hemodynamic parameters were
recorded before and after induction and extubation. After
the completion of surgery, when spontaneous recovery of
neuromuscular blockade occurs with the appearance of T2,
anesthesia was withdrawn and the neuromuscular block
was reversed using a single intravenous dose of neostigmine
(50 mg/kg) plus atropine (15 mg/kg) in Group 1, and a single
intravenous dose of sugammadex (4.0 mg/kg) in Group 2.
The primary efficacy endpoint for extubation was the time
from sugammadex or neostigmine administration to recov-
ery of the TOF ratio to 0.9. Operation time (time from skin
incision to end of surgery) and adverse events (gagging,
nausea, vomiting, breath holding, laryngospasm, and







Age (y) 33.87  13.85 33.60  12.92 0.93
Sex (male/female) 20/10 19/11 0.78
Height (cm) 173.48  8.4 172.93  8.56 0.80
Weight (kg) 81.33  12.05 76.07  12.98 0.10
Body mass index
(kg/m2)
27.02  4 26.3  3.95 0.61
ASA (I/II) 12/18 16/14 0.30
Duration of
anesthesia (min)
95.40  37.56 80.93  32.53 0.11
*p < 0.05 (significant).
ASA Z American Society of Anesthesiologists.
Figure 1. Mean arterial pressure at each time interval from
baseline to 30 minutes after tracheal extubation. Bars repre-
sent standard deviation. aZ p < 0.05 compared with baseline
value.
82 S. Hakimoglu et al.tremors) were recorded. Modified Aldrete Recovery Score
(MAS) was used as recovery criteria and the time to reach
MAS > 8 was recorded. Hemodynamic parameters (heart
rate, mean arterial pressure, peripheral arterial oxygen
saturation) were measured before induction and at 30 sec-
onds, 2 minutes, 10 minutes, and 30 minutes after extu-
bation; IOPs were measured before induction and at
30 seconds, 2 minutes, and 10 minutes after extubation.
Those with a baseline IOP of >30 mmHg were excluded.
Tono-Pen XL applanation tonometer (Medtronic Solan,
Jacksonville, FL, USA) was used to measure IOP. The
tonometer was calibrated prior to each use. The IOP values
of the patients were checked after application of one drop
of sterile eye drop tetracaine 0.5% by an applanation
tonometer.
Power analysis
Our primary hypothesis was that the used sugammadex
resulted in a larger decrease in IOP after endotracheal
intubation. Sample size estimation was based on the stan-
dard deviation of a similar study performed by Igboko et al.
[17]. We used the IOP values after endotracheal tube
extubation (17.1  3.3 mmHg) determined by Igboko et al.
[17]. To detect a 15% change in IOP, with an a error of 0.05,
and a power of 90%, we calculated that the sample size
should be at least 24 patients/group. Estimating an
approximately 25% dropout rate, we included 30 patients in
each group. The sample size estimation was performed
using Power Calculator (Department of Statistics, University
of California, Los Angeles; http://www.stat.ubc.ca/_
rollin/stats/ssize).
Statistical analysis
Statistical analysis was performed using SPSS for Windows
version 15.0 (SPSS Inc., Chicago, IL, USA). Student t test
was used to compare measurements between groups while
a paired sample t-test was used for intragroup comparisons.
Chi-square test was used to compare categorical variables.
A p value <0.05 was considered statistically significant.
Results
No significant differences were detected between groups
when demographic data and anesthesia time were
compared (Table 1).
When mean arterial pressure measurements were
compared, there were significant differences between
basal values and those obtained at 30 seconds, 10 minutes,
and 30 minutes after extubation in the neo-
stigmineeatropine group (p Z 0.013; p Z 0.035; and
p Z 0.001, respectively). In the sugammadex group, there
were significant differences between basal values and
those obtained at 30 seconds and 2 minutes after extuba-
tion (p Z 0.01 and p Z 0.046, respectively). No significant
difference in mean arterial pressure was detected when
groups were compared at all other time points (p > 0.05 for
all; Figure 1).
When heart rate was compared, there was a significant
difference between basal values and those obtained at30 seconds and 10 minutes after extubation in the neo-
stigmineeatropine group. In the sugammadex group, there
was also a significant difference between basal values and
those obtained at 30 seconds and 10 minutes after extu-
bation. There was a significant difference in heart rate
values obtained at 10 minutes after extubation compared
with heart rate values at all other time points (p < 0.01;
Figure 2).
When IOP values were compared, no significant differ-
ences were detected between groups (p > 0.05). In intra-
group comparisons, IOP values measured before induction
were lower than those obtained at all other time points in
both groups (Figure 3), but a significant difference was
detected only between IOP values measured before in-
duction and those measured at 30 seconds after extubation
(p Z 0.004 and p Z 0.001, respectively).
Extubation time (time from withdrawal of anesthetic gas
to extubation) was significantly shorter in the sugammadex
group (pZ 0.003) than in the neostigmineeatropine group.
The time to reach MAS > 8 was also shorter in the
Figure 2. Heart rate at each time interval from baseline to
30 minutes after tracheal extubation. Bars represent standard
deviation. a Z p < 0.05 compared with baseline value.
b Z p < 0.05 compared with the sugammadex group.
Figure 3. Intraocular pressure at each time interval from
baseline to 30 minutes after extubation. Bars represent stan-
dard deviation. a Z p < 0.05 compared with baseline value.
Table 2 Comparison of the groups according to extuba-







MAS > 8 7.87  3.34 8.43  2.95 0.489
Extubation time
(min)
3.03  1.29 4.18  1.49* 0.003
*p < 0.05 (significant).
MAS Z Modified Aldrete Recovery Score.











Breath-hold 3 4 > 0.99
Laryngospasm 1 1 > 0.99
Shivering 4 8 0.333
Cough 5 5 > 0.99
*p < 0.05 (significant).
Effect of reversal agents on intraocular pressure 83sugammadex group, but the difference did not reach sta-
tistical significance (Table 2). When complications were
assessed, it was found that nausea, vomiting, breath
holding, and tremors were more common in the neo-
stigmineeatropine group than in the sugammadex group,while laryngospasm and cough were equally common in
both groups (Table 3).
Discussion
In this study, we observed that sugammadex used in the
reversal of nondepolarizing neuromuscular blockage did not
affect IOP such as neostigmineeatropine. Also, IOP values
measured before induction were lower than those obtained
at all other time points in the two groups.
There are several studies about the effects on IOP of
interventions used during anesthesia. Anesthesia-related
factors, such as premedication drugs, general anesthetics,
and lung ventilation, are also known to affect IOP. Uncon-
trolled increase of IOP may lead to staining of the cornea
with blood, obstruction of retinal arterioles, and optic
atrophy.
In one such study, it was shown that tracheal intubation
caused higher values in IOP when compared with Laringeal
mask airway or I-gel [18,19]; however, to the best of our
knowledge, there is no study comparing the effects of
sugammadex and neostigmine on IOP. In this study, we
observed that sugammadex used in reversal of non-
depolarizing neuromuscular blockade did not affect IOP.
In a study by Madan et al. [8], the effects of tracheal
intubation and extubation on IOP were investigated in both
healthy children and those with glaucoma. Neostigmine
(50 mg/kg) was used to reverse neuromuscular block in that
study, and IOP values at 30 seconds and 2 minutes after
extubation were found to be higher when compared with
those obtained before intubation [8]. By contrast, our study
was conducted on adult patients.
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caused similar changes in IOP. When IOP changes were
assessed within the groups, a significant difference was
observed between IOP values only at 30 seconds after
extubation and those obtained before anesthesia
induction, although there were elevations in IOP values
after extubation in both groups. Based on our results, it can
be suggested that reversal with sugammadex had no
prominent negative effect on IOP. In a previous case, it was
reported that IOP was maintained at <20 mmHg during
extubation in a patient with a history of narrow-angle
glaucoma who underwent surgery for a femoral neck
fracture [20].
It is also known that neostigmine can cause bradycardia
through direct activation of cholinergic receptors in the
peripheral cardiac parasympathetic pathway, which can be
prevented by atropine [21,22]. In our study, mean arterial
pressure and heart rate were found to be higher in the
sugammadex group compared with those in the neo-
stigmineeatropine group despite the lack of a significant
difference. In the neostigmineeatropine group, the heart
rate was higher at 30 seconds and lower at 10 minutes after
extubation when compared with baseline values; however,
in the sugammadex group, the heart rate was higher at
30 seconds and 2 minutes after extubation when compared
with baseline values. In addition, heart rate was lower at
10 minutes after extubation in the neostigmineeatropine
group, while no significant difference in mean arterial
pressure was detected between the groups. In a study by
Jones et al. [23], it was reported that heart rate and mean
arterial pressure were higher at 2minutes, 5 minutes, and
10 minutes after neostigmine administration but not after
sugammadex administration when compared with baseline
values. In a study by Lemmens et al. [24], it was shown that
sugammadex had no significant effect on blood pressure,
heart rate, ventilation, or thermoregulation. In another
study, Koc¸ et al. [25] compared neostigmine plus atropine
with sugammadex and reported that there was no signifi-
cant difference in systolic and diastolic arterial pressures or
heart rate. The authors found that heart rate was signifi-
cantly decreased at 6 minutes after neostigmineeatropine
administration, but no such decrease was detected in the
sugammadex group.
In studies on the pharmacokinetic properties of sugam-
madex, it was shown that sugammadex reverses the
neuromuscular block induced by rocuronium and vecuro-
nium in a rapid and effective manner. In dose-dependent
studies, it was shown that sugammadex is also effective in
reducing profound blockades [26e29]. The recommended
dose of sugammadex is 2 mg/kg for a superficial block and
4 mg/kg for a profound block induced by neuromuscular
blocking agents. Jones et al. [23] demonstrated that 4 mg/
kg sugammadex reversed the neuromuscular relaxant ef-
fect of rocuronium more rapidly than neostigmine (70 mg/
kg) plus glycopyrrolate (14 mg/kg). In a study on morbidly
obese patients, Gaszysnki et al. [30] demonstrated that
2 mg/kg sugammadex provided more rapid reversal of
neuromuscular functions than 50 mg/kg neostigmine and
prevented residual curarization. In another study, it was
shown that sugammadex markedly diminished extubation
time when compared with neostigmineeatropine [26]. The
results of our study agreed with those of previous studies inthat extubation time was significantly shorter in the
sugammadex group (p Z 0.003) than in the neo-
stigmineeatropine group. In addition, the time to reach
MAS > 8 was shorter in the sugammadex group but the
difference was not statistically significant.
In a study on 1444 patients by Ledowski et al. [31], it was
reported that the incidence of postoperative nausea and
vomiting was higher in patients who received neostigmine,
and that sugammadex use might reduce the risk of pulmo-
nary complications in elderly patients with a risk status of
American Society of Anesthesiologists IIIeIV. In our study,
there was no significant difference in complications be-
tween groups, but nausea, vomiting, breath holding, and
tremors were more common in the neostigmineeatropine
group, while laryngospasm and cough were equally common
in both groups.
Not including the control group as well as the groups
including the 2-mg/kg dose of sugammadex, has inevitably
constricted the scope of the study. The effects of sugam-
madex on IOP may be examined in another study including
these groups and a higher number of patients.
In conclusion, the postextubation IOP values of the
sugammadex group were similar to the neo-
stigmineeatropine group. Additionally, in agreement with
previous studies, in our study extubation time was found to
be shorter in the sugammadex group than in the neo-
stigmineeatropine group. Further studies are needed that
include more patients.References
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